Sie suchten nach: rinotraheitisa (Kroatisch - Englisch)

cjepivo protiv virusnog rinotraheitisa i kaliciviroze mačaka.
vaccine against feline viral rhinotracheitis and feline calicivirosis.

protiv virusnog rinotraheitisa mačaka radi smanjenja kliničkih znakova,
against feline viral rhinotracheitis to reduce clinical signs,

potiče aktivni imunitet protiv herpesvirusa, rinotraheitisa i kaliciviroze mačaka.
stimulates active immunity against feline rhinotracheitis herpesvirus and feline calicivirus.

virusnog rinotraheitisa mačaka, radi smanjenja kliničkih simptoma i izlučivanja virusa,
feline viral rhinotracheitis to reduce clinical signs and viral excretion,

cjepivo protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka i panleukopenije mačaka.
vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia.

atenuirani herpesvirus rinotraheitisa mačaka (soj fhv f2) ........................................  104,9 ccid501
attenuated feline rhinotracheitis herpesvirus (fhv f2 strain) ......................................  104.9 ccid501

cjepivo protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka i panleukopenije i leukemije mačaka.
vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

atenuirani herpes virus rinotraheitisa mačaka (soj fhv f2) ........................................  104,9 ccid 1
attenuated feline rhinotracheitis herpesvirus (fhv f2 strain) .......................................  104.9 ccid 1

cjepivo protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka, klamidioze mačaka i panleukopenije mačaka.
vaccine against feline viral rhinotracheitis, feline calicivirosis, chlamydiosis and feline panleucopenia.

cjepivo protiv virusnog rinotraheitisa mačaka, kaliciviroze mačaka, klamidioze mačaka, panleukopenije i mačje leukemije.
vaccine against feline viral rhinotracheitis, feline calicivirosis, chlamydiosis, feline panleucopenia and feline leukaemia.

potiče aktivni imunitet protiv herpesvirusa rinotraheitisa mačaka, kaliciviroze mačaka, klamidioze mačaka i virusa panleukopenije mačaka.
stimulates active immunity against feline rhinotracheitis herpesvirus, feline calicivirus, chlamydophila felis and feline panleucopenia virus.

trajnost imuniteta nakon zadnje re-vakcinacije je 3 godine protiv komponenti rinotraheitisa, kalici virusa i panleukopenije.
the duration of immunity after the last re-vaccination is 3 years for rhinotracheitis, calicivirosis and panleucopenia components.

aktivna imunizacija goveda za smanjenje kliničkih znakova zaraznog rinotraheitisa goveda (zrg) i izlučivanja virusa u okoliš.
active immunisation of cattle to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.

prva revakcinacija mora biti provedena jednu godinu nakon prvog cijepljanja, naknadne revakcinacije moraju biti provedene u intervalima od najviše tri godine za komponente rinotraheitisa i kalicivirusa.
the first revaccination must be carried out one year after the primary vaccination course, subsequent revaccinations must be carried out at intervals of up to three years for the rhinotracheitis and calicivirosis components.

fevaxyn pentofel potiče razvoj aktivnog imuniteta na virus mačje panleukopenije, virus mačjeg rinotraheitisa, mačji kalicivirus, chlamydophile felis i virus mačje leukemije.
fevaxyn pentofel stimulates the development of active immunity against feline panleucopenia virus, feline rhinotracheitis virus, feline calicivirus, chlamydophila felis and feline leukaemia virus.

trajnost imuniteta nakon zadnje re-vakcinacije je 3 godine za komponente rinotraheitisa, kaliciviroze i panleukopenije i 1 godinu za komponente chlamydophila felis i leukemiju mačaka.
the duration of immunity after the last re-vaccination is 3 years for the rhinotracheitis, calicivirosis and panleucopenia components, and 1 year for the chlamydophila felis and feline leukaemia components.

podaci o neškodljivosti i djelotvornosti su dostupni i dokazujuda se ovo cjepivo smije pomiješati i primijeniti s ne adjuviranim cjepivima merial koja sadrže različite kombinacije komponenti protiv virusnog rinotraheitisa mačaka, kaliciviroze, panleukopenije i klamidioze mačaka.
safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with merial non-adjuvanted vaccines containing various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components.

podaci o neškodljivosti i djelotvornosti su dostupni i dokazuju da se ovo cjepivo smije pomiješati i primijeniti s ne adjuviranim merial cjepivima koja sadrže različite kombinacije komponenti protiv virusnog rinotraheitisa mačaka, kaliciviroze, panleukopenije i klamidioze mačaka.
safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with merial non-adjuvanted vaccines containing various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components.

podaci o neškodljivosti i djelotvornosti su dostupni, što je dokaz da ovo cjepivo smije biti pomiješano i primijenjeno s paletom neadjuviranih cjepiva tvrtke merial (različite kombinacije komponenti protiv virusnog rinotraheitisa, kaliciviroze, panleukopenije i klamidioze mačaka.
safety and efficacy data are available which demonstrate that this vaccine can be mixed and administered with merial non-adjuvanted vaccine range (various combinations of feline viral rhinotracheitis, calicivirosis, panleukopenia and chlamydiosis components)

kada se očekuje prisutnost visoke razine majčinih antitijela protiv komponenti rinotraheitisa, kaliciviroze, panleukopenije ili chlamydophila (npr. kod mačića u dobi 9-12 tjedana porijeklom od mačaka cijepljenih prije graviditeta i/ili s poznatim ili suspektnim prethodnim izlaganjem patogenima), prvo cijepljenje treba odgoditi do dobi od 12 tjedana.
where high levels of maternal antibodies against rhinotracheitis, calicivirosis, panleucopenia or chlamydophila components are expected to be present (e.g. in kittens of 9–12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.